Rapport Therapeutics (RAPP) Total Non-Current Liabilities (2023 - 2024)
Rapport Therapeutics (RAPP) posted quarterly Total Non-Current Liabilities of $74000.0 for Q4 2024, down 99.28% year-over-year from $10.3 million in Q1 2024, and down 99.28% quarter-over-quarter from $10.3 million in Q4 2023.
Rapport Therapeutics (RAPP) Total Non-Current Liabilities (2023 - 2024) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Total Non-Current Liabilities for 2 consecutive years, with $74000.0 the latest figure, recorded in Q4 2024.
- In Q4 2024, Total Non-Current Liabilities fell 99.28% year-over-year to $74000.0; the TTM figure through Dec 2024 stood at $74000.0 (down 99.28% YoY), while the FY2024 annual figure was $74000.0, down 99.28% from the prior year.
- Total Non-Current Liabilities slipped to $74000.0 in Q4 2024 per RAPP's latest filing, from $10.3 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $10.3 million in Q4 2023 and bottomed at $74000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 74,000.00 |
| Dec 31, 2023 | 10.28 Mn |